
Home » A&G AND CELLTRION FORM ANTICANCER ALLIANCE
A&G AND CELLTRION FORM ANTICANCER ALLIANCE
June 9, 2006
A&G Pharmaceutical and South Korean biopharmaceutical company Celltrion have entered into an agreement for clinical production of A&G's theranostic monoclonal antibody for the treatment of cancer. Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as phase I and phase II US clinical studies on A&G's anti-GP88 monoclonal antibody. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=9C81CF28-2508-4AD7-8A73-61715E44CFE4)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
19Jan
-
21Jan
-
26Jan
-
27Jan
-
27Jan
-
09Feb